Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.54 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862340 | 0.92 | TLR7 (0.59) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL5350377 | 0.90 | TLR7 (0.57) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL8137411 | 0.89 | TLR7 (0.56) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL13613828 | 0.88 | TLR7 (0.55) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL6862807 | 0.87 | TLR7 (0.58) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL5106888 | 0.84 | TLR7 (0.55) | TLR7TLR8NUDT1 | |
| SCHEMBL13613829 | 0.83 | TLR7 (0.48) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL4330519 | 0.83 | KMT2A (0.43) | LMNAPOLBGBA1 | |
| SCHEMBL18588039 | 0.83 | TLR7 (0.52) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL5106863 | 0.82 | TLR7 (0.61) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612083-B2 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1341790-B1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7132429-B2 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-7115622-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-7078523-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-7049439-B2 | Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1343784-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050234088-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-20 | — | — | US | disclosed |
| EP-1341792-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1341790-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-21 | — | — | US | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-19 | — | — | US | disclosed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046188-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885LMNA 4649/4885 |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885LMNA 3769/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885LMNA 4649/4885 |
| US-20050234088-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 74/4885TLR8 257/4885LMNA 3110/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885LMNA 3769/4885 |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885TLR8 51/4885LMNA 3479/4885 |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885LMNA 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.